We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




World's First Reusable Biochip Architecture Designed

By LabMedica International staff writers
Posted on 07 Jul 2010
The world's first reusable biochip architecture has been developed for the commercial market. More...
These reusable integrated fluidic circuits (IFCs) will dramatically lower single nucleotide phenotype (SNP) genotyping costs and are designed to support accelerated sample throughput, while maintaining data quality of 99.75% or greater accuracy and 99% or greater call rates.

Fluidigm Corp. (South San Francisco, CA, USA) initially invented this architecture to support a progressive new program driven by the Agricultural Research Service (ARS; Washington, DC, USA), the chief scientific research agency of the United States Department of Agriculture (USDA). The program's goal is to drive high sample throughput genotyping down to a penny-per-data-point, which would enable widespread adoption of genetic analysis in vegetable and fruit seeds, livestock (such as cattle, pigs, sheep, poultry), and fishery management. This will significantly improve the quality and quantity of the food supply, while lowering production costs.

Fluidigm's new reuse architecture represents the first step towards making this goal a reality. "We are elated that Fluidigm's reusable biochip can contribute to improving the food supply and bring the benefits of genetic analysis and testing to AgBio scientists and producers around the globe,” said Gajus Worthington, president and chief executive officer of Fluidigm. "A year ago, when we set out to develop a reusable chip, the notion was controversial. But we thought the idea was compelling--and so did our customers. I am so pleased that our scientists and engineers weren't inhibited by traditional thinking that believed reusability in the microfluidic device was impossible. Instead of acquiescing to the norm, they overcame the dogma of the past and achieved an engineering marvel. I believe reusability will be revolutionary for our industry and the life science fields we serve. Reusability lowers costs, eliminates waste, and confers flexibility. I can't think of an invention we've made at Fluidigm that has excited me more.”

Mr. Worthington noted that the company had also recently introduced an ultra-fast thermal cycler--the FC1 Cycler--and is adding a new IFC controller designed to support reusable chips. Initially the reuse family of products will include chips, a new controller, the FC1 Cycler, and either the EP1 Reader or the BioMark system. A new chip and instrument will be announced soon to start high-sample throughput genotyping customers down the reusable path. "We expect to bring additional chip configurations, instruments, and assays to the market place over this year and next that will make reusability practical for more customers, continue to lower costs per data point and set a course for genetic analysis to contribute to a better food supply for the world,” stated Mr. Worthington.

Application of Fluidigm's reuse technology will also contribute to the life-science industry's competitiveness. "We have recently added the Fluidigm system to the family of genomic services we offer our clients. We are seeing a great and growing need for high quality, cost-effective genetic testing services from plant and animal researchers. We have done some work in this area, but cost has always been a barrier. Fluidigm's new reusable chips will enable our agriculture-based customers to realize the tremendous benefits of SNP genotyping at significantly reduced costs,” said Steve McPhail, Expression Analysis's president and chief executive officer. Expression Analysis, Inc. (Durham, NC,USA) is a leading provider of genomic services for clinical trials and research.

Fluidigm develops, manufactures, and markets proprietary IFC systems that significantly improve productivity in life science research. Fluidigm's IFCs enable the simultaneous performance of thousands of sophisticated biochemical measurements in extremely minute volumes.

Related Links:

Fluidigm



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Integrated Biochemical & Immunological System
Biolumi CX8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.